Chest Medicine
[Preprint] Systematic Review: Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease – “effectiveness against COVID-19 severe disease remained high (>70%) in most studies in the six months after full vaccination, although it did decrease some (on average, 8-10 percentage points) between one and six months after full vaccination”.
23 Nov, 2021 | 08:57h | UTCRelated:
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.
China’s COVID vaccines have been crucial — now immunity is waning.
Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.
COVID vaccine effects wane over time but still prevent death and severe illness.
Perspective | What we actually know about waning immunity.
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Studies: COVID vaccine protection waning against infection but not hospitalization.
Populational study in France did not show an increased incidence of acute myocardial infarction, stroke, and pulmonary embolism following the Pfizer vaccine.
23 Nov, 2021 | 08:51h | UTC
M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.
23 Nov, 2021 | 08:55h | UTCNews release: Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death – BMJ
Original Study: Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials – RMD Open
Related:
United States FDA clears COVID vaccine boosters for all adults over 18 – Pfizer & Moderna 6 months after second jab.
21 Nov, 2021 | 23:17h | UTCSee also:
FDA expands emergency authorization for Covid-19 booster shots to all adults – STAT
FDA, CDC advisors approve COVID boosters for all US adults – CIDRAP
FDA Approves Both Pfizer, Moderna Boosters for All Adults – HealthDay
EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.
21 Nov, 2021 | 23:14h | UTCRelated:
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.
21 Nov, 2021 | 23:15h | UTC
Commentary on Twitter
NEW Personal View—Non-invasive respiratory support in the management of acute #COVID19 #pneumonia: considerations for clinical practice and priorities for research
From Prof Hugh Montgomery & colleagues https://t.co/LLEFz2VLFu pic.twitter.com/owgAjLX5Z6
— The Lancet Respiratory Medicine (@LancetRespirMed) November 10, 2021
M-A: Convalescent plasma does not reduce mortality in COVID-19.
21 Nov, 2021 | 23:09h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – “The IFR was low for people younger than 51 years without comorbidity during the two waves (combined IFR = 3.36 per 100,000 infections)”.
21 Nov, 2021 | 23:12h | UTC
Commentary on Twitter
New in JID: A study in Denmark found that the SARS-CoV-2 infection fatality rate was low for people younger than 51 and otherwise healthy, increased with age and comorbidities, and declined from the 1st to the 2nd wave of the pandemic.
📄 https://t.co/lenryomRJ3 #IDSAJournals pic.twitter.com/TT8RefGjHw
— IDSA (@IDSAInfo) November 20, 2021
Is Delta the last Covid ‘super variant’?
21 Nov, 2021 | 23:07h | UTCIs Delta the last Covid ‘super variant’? – The Guardian
RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.
19 Nov, 2021 | 11:01h | UTCInvited Commentary: Studying the coagulopathy of COVID-19 – The Lancet
Commentary from the author on Twitter (thread – click for more)
RECOVERY Publication: ASPIRIN
(a widely used anti-platelet treatment in other settings)14 892 patients hospitalised with COVID-19.
No impact on mortality.
Small improvement in hospital stay.
No impact on need for mechanical ventilation
6 more bleeds. 6 fewer thromboses (clots) pic.twitter.com/LxDzudss9F— Martin Landray (@MartinLandray) November 18, 2021
WHO global report on trends in prevalence of tobacco use 2000-2025.
19 Nov, 2021 | 10:43h | UTCNews Release: Tobacco use falling: WHO urges countries to invest in helping more people to quit tobacco – World Health Organization
Commentary on Twitter
Tobacco use is falling by 5⃣ million people per year
🆕 WHO global tobacco trends report released today, shows that there are 1.3 billion tobacco users 🌐 compared to 1.32 billion in 2015, & expected to ↘️ to 1.27 billion by 2025.
👉 https://t.co/o3bdYaQy84#CommitToQuit 🚭 pic.twitter.com/gSJebhRtYY
— World Health Organization (WHO) (@WHO) November 16, 2021
AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.
19 Nov, 2021 | 10:34h | UTCBiologics for Asthma and Allergic Skin Diseases in Children – Pediatrics
M-A: Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality.
18 Nov, 2021 | 08:59h | UTC
Commentary on Twitter
Experts call for continued use of personal protective and social measures alongside covid-19 vaccination in @bmj_latest today https://t.co/MOT4O2R6Ui pic.twitter.com/dAxhStSxpJ
— BMJ Group (@bmj_company) November 18, 2021
[Preprint] M-A: Inhaled corticosteroids in COVID-19 outpatients.
18 Nov, 2021 | 08:48h | UTCInhaled Corticosteroids for Outpatients with Covid-19: A Meta-Analysis – medRxiv
Commentary: Favourable meta-analysis of inhaled corticosteroids in COVID-19 outpatients – News Medical
Related:
Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.
RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19
Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19
Commentary on Twitter
The first meta-analysis of the 4 completed & reported trials of outpatient inhaled corticosteroid #COVID19 treatment
The results support the use of inhaled corticosteroids (ciclesonide or budesonide) for the resolution of symptoms at day 14 of treatmenthttps://t.co/KnBDKhfYmi pic.twitter.com/WSd9htXwe4— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) November 5, 2021
Observational study finds the effectiveness of mRNA vaccination against Covid-19 hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%).
18 Nov, 2021 | 08:52h | UTCRelated:
CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.
Commentary on Twitter (thread – click for more)
New CDC study of mRNA #vaccination & disease in 89,000 ppl hospitalized w/#COVID19
– 69K had normal immune systems; 1/2 of them were 2-dose vaxed
– 20K had systs weakened by cancer or other illnesses, 25% of whom were unvaxed
– Vax was 90% effective in preventing severe…
MORE pic.twitter.com/w3RFCrQnLB— Laurie Garrett (@Laurie_Garrett) November 2, 2021
Case-control study: sleep disorders linked to more severe outcomes from COVID-19, study suggests.
17 Nov, 2021 | 08:50h | UTCNews Release: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic
Commentary: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP
Commentary on Twitter
This case-control study found that among patients infected with #SARSCoV2, sleep-related hypoxia was an associated risk factor for detrimental #COVID19 outcomes. https://t.co/oWjPxBSxT8
— JAMA Network Open (@JAMANetworkOpen) November 10, 2021
Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes.
17 Nov, 2021 | 08:53h | UTCNews Release: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine
Commentaries:
Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist
Texting saved lives during Covid. What does that mean for health care’s future? – STAT
Commentary from the author on Twitter (thread – click for more)
1/ For the >80,000 people in the U.S who will test positive for #Covid19 today, what can we offer to support access to care but help them safely remain at home?
Our team is excited to finally share important, new findings out today in @AnnalsofIM
👉https://t.co/VOtpucwWGD pic.twitter.com/UbNRP5bnW4— M. Kit Delgado, MD, MS (@kit_delgadoMD) November 16, 2021
The big questions about Covid-19 booster shots – “From the why to the who, we still need a lot of answers about booster shots”.
17 Nov, 2021 | 08:48h | UTCThe big questions about Covid-19 booster shots – Vox
Commentary on Twitter
1/ Thoughtful piece by @voxdotcom's @germanrlopez on COVID vaccine boosters.
In good company with @ashishkjha @DrPaulOffit @MonicaGandhi9 @jenkatesdc.https://t.co/pOwZLkmJHn pic.twitter.com/ZAD7AOj0Vz
— Céline Gounder, MD, ScM, FIDSA 🇺🇦 (@celinegounder) November 12, 2021
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
17 Nov, 2021 | 08:42h | UTCRelated:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.
16 Nov, 2021 | 08:48h | UTC
Commentary on Twitter
NEW Research—In pts w/ #COVID19 who received IMV for mod-to-sev #ARDS, intravenous immunoglobulins did not improve clinical outcomes at day 28
Phase 3 ICAR trial from Prof Tarek Sharshar & colleagues https://t.co/TBWxngXIPT pic.twitter.com/W2dNBaM1o1
— The Lancet Respiratory Medicine (@LancetRespirMed) November 12, 2021
IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.
16 Nov, 2021 | 08:50h | UTCNews Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology
Review: Vaccine-induced immune thrombotic thrombocytopenia.
16 Nov, 2021 | 08:46h | UTCVaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology
Related:
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
NEW Viewpoint by @Erik_Klok_MD, @MPaiMD, Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine https://t.co/FI4NynwzEn pic.twitter.com/9PbjaioA2T
— The Lancet Haematology (@TheLancetHaem) November 12, 2021
Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.
16 Nov, 2021 | 08:41h | UTCPfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation
Related:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.
16 Nov, 2021 | 08:39h | UTCRelated:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
M-A: Prediction of extubation outcome in critically ill patients.
16 Nov, 2021 | 08:27h | UTC